Answers are grounded in this paper and cite their sources.
This study of somatic mutations in melanoma is the last prospectively collected phase III clinical trial population before the era of BRAF-targeted therapy. A trend toward improved clinical response in patients with NRAS-mutant melanoma treated with CPS was observed, possibly due to the effect of sorafenib on CRAF.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: